1228 related articles for article (PubMed ID: 20061941)
1. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
2. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
3. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
6. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
8. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
11. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
12. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
13. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
14. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
15. Roles for lysophospholipid S1P receptors in multiple sclerosis.
Noguchi K; Chun J
Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
[TBL] [Abstract][Full Text] [Related]
16. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
[TBL] [Abstract][Full Text] [Related]
17. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
18. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Soliven B; Miron V; Chun J
Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
20. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
Samuvel DJ; Saxena N; Dhindsa JS; Singh AK; Gill GS; Grobelny DW; Singh I
PLoS One; 2015; 10(10):e0141781. PubMed ID: 26513477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]